Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27962371 | 1.00 | ZDHHC7 (0.47) | ZDHHC7CPB2GPR84FFAR1MAPT | |
| SCHEMBL26105313 | 1.00 | ZDHHC7 (0.47) | ZDHHC7CPB2GPR84FFAR1MAPT | |
| SCHEMBL27962385 | 0.98 | ZDHHC7 (0.44) | ZDHHC7CPB2GPR84FFAR1MAPT | |
| SCHEMBL6817900 | 0.92 | CA2 (0.44) | ZDHHC7CPB2CA2 | |
| SCHEMBL2865545 | 0.92 | CPB2 (0.47) | ZDHHC7CPB2 | |
| SCHEMBL27962361 | 0.90 | FAAH (0.54) | FFAR1MAPTPPARDFAAHFFAR4 | |
| SCHEMBL6761975 | 0.87 | CPB2 (0.43) | CPB2 | |
| SCHEMBL8027706 | 0.86 | NAAA (0.47) | ZDHHC7GPR84FFAR1MAPTLCK | |
| SCHEMBL29190360 | 0.86 | ZDHHC7 (0.48) | ZDHHC7GPR84FFAR1MAPTLCK | |
| SCHEMBL30791313 | 0.86 | ZDHHC7 (0.48) | ZDHHC7GPR84FFAR1MAPTLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103910741-B | Bisbenzylisoquinolincompounds trimethyl-glycine and preparation method thereof and the application in antitumor drug preparation | Shangdong Normal University (CN) | 2016-04-13 | — | — | CN | claimed |
| CN-103910741-A | Bisbenzylisoquinoline betaine as well as preparation method thereof and application thereof in preparation of anti-tumor medicament | UNIV SHANDONG NORMAL | 2014-07-09 | — | — | CN | claimed |
| CN-103910738-B | A kind of Bisbenzylisoquinolincompounds quaternary ammonium salt and preparation method thereof and the application in preparing antitumor drug | 山东师范大学 | 2016-07-06 | — | — | CN | disclosed |
| CN-103910741-B | Bisbenzylisoquinolincompounds trimethyl-glycine and preparation method thereof and the application in antitumor drug preparation | Shangdong Normal University (CN) | 2016-04-13 | — | — | CN | disclosed |
| EP-1303527-B1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMA AS (DK) | 2004-09-29 | — | — | EP | disclosed |
| EP-1303527-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Leo Pharma A/S (DK) | 2003-04-23 | — | — | EP | disclosed |
| US-6521606-B2 | 2-(4-Chlorophenoxy)-2-oxo-1,3,2-oxazaphosphorinane-3-aceto -hydroxamic acid, for example; antiathritic, -tumor, -metastasis, -proliferative and -ulcer agents; multiple sclerosis; vision defects; skin disorders | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2003-02-18 | — | — | US | disclosed |
| US-20020103166-A1 | Matrix metalloproteinase inhibitors | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2002-08-01 | — | — | US | disclosed |
| WO-2002006293-A1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMA A/S (DK) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103166-A1 | Matrix metalloproteinase inhibitors | MMP1, MMP9, MMP8 | ZDHHC7 654/4885CPB2 1861/4885GPR84 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.